Evidence analysisNovember 13, 2026Health & Science
With the new shift in the U.S. Congress, time is running out on bills targeting drug patents

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
What is established
A set of bipartisan bills aimed at reforming drug patent laws in the United States is facing a critical deadline before the new Congress convenes in January 2027. These bills seek to address strategies used by pharmaceutical companies to extend monopolies on drugs beyond their original patent terms, thereby delaying the introduction of cheaper generic or biosimilar alternatives.
The bills notably include:
- The ETHIC Act, which would cap the number of related patents a company can use when suing competitors to market cheaper versions of a drug.
- The Drug Competition Enhancement Act, designed to prevent companies from shifting patients to slightly altered versions of a drug primarily to prolong patent protections.
- The Medication Affordability and Patent Integrity Act, which would require consistent and truthful information from drugmakers submitted simultaneously to the FDA and U.S. Patent Office, to prevent contradictory claims used to delay competition.
- Other legislation to simplify pharmacist substitution of cheaper biologic drugs for the brand versions prescribed by doctors.
The context is the prolonged and expensive monopoly situation exemplified by Merck & Co’s cancer drug Keytruda, which has been held under patent protection since its debut and now reportedly has a “fortress” of dozens of patents extending monopoly rights potentially through 2042, well beyond the expiration of its original patent.
What the source claims
The International Consortium of Investigative Journalists (ICIJ) reports that without legislative action before January 2027, these bills risk being stalled or having to restart the legislative process under a newly configured Congress, possibly jeopardizing their chances of becoming law.
ICIJ’s investigation highlights how companies like Merck have used numerous related patents to delay cheaper biosimilar competition, resulting in extremely high drug prices—for Keytruda, annual costs can range from approximately $80,000 to over $200,000 internationally—and limited accessibility for many patients.
Supporters of the reform bills argue that they would help bring lower-cost medicines to market more quickly by preventing patent “gamesmanship.” Opponents, including powerful business groups like the U.S. Chamber of Commerce and pharmaceutical industry trade groups such as PhRMA, warn these measures could weaken patent protections and potentially harm innovation incentives.
ICIJ notes that key legislators supporting reform, such as Rep. Lloyd Doggett, criticize ongoing pharmaceutical influence in Congress as a major obstacle, describing industry lobbying efforts as extensive and effective.
What may be missing from the usual framing
The discussion often omits deeper analysis of the balance between innovation incentives and access to medicines. While patent extensions may delay competition and contribute to high prices, patents also represent critical rewards for drug innovation. This balance is complex and contextual.
The influence of pharmaceutical lobbying is acknowledged but without detailed evidence of precise mechanisms or direct impacts on specific votes or legislative language changes. The tension between public health benefits of cheaper drugs and private sector interests in maximizing patent durations remains a complicated dynamic.
Additionally, international comparisons beyond a few examples (such as Argentina’s regulatory environment and recent Dutch court rulings) are limited. More evidence could elucidate how different legal frameworks impact access and pricing globally.
Competing evidence or uncertainty
Merck disputes the characterization that companies use multiple patents primarily as anti-competitive tools, calling it a “common myth.” They argue that the number of patents does not determine when generics or biosimilars enter the market. This assertion remains uncorroborated in the report.
The U.S. Patent Office rulings have at times sided with Merck in patent disputes, suggesting that some patents may have legitimate grounds. Ongoing court cases and patent reviews (such as with Halozyme’s delivery technology patents) illustrate that the situation is legally complex, not purely a matter of abuse.
Lobbying groups contend these bills are based on “faulty and misleading narratives” and warn of unintended negative consequences on innovation. Such positions underline the uncertainty regarding optimal policy solutions and open questions about the actual impacts of these reforms on drug development incentives.
Why it matters
The outcome of this legislative push could significantly influence access to affordable medicines in the U.S., particularly for biologics and cancer treatments. With key cancer drugs like Keytruda remaining exorbitantly priced, reform could alleviate financial burdens on patients and healthcare systems.
Conversely, if the bills fail, the status quo of extended patent protections could continue, potentially keeping prices high and delaying competition. The political balance of power and influence of pharmaceutical lobbying may determine whether reforms succeed or stall, affecting public health outcomes for years.
Furthermore, this scenario highlights broader issues around pharmaceutical policy, patent law, lobbying influence, and the public’s role in shaping health innovation governance.
What to verify next
- Track the legislative progress of these bills as the year closes and the new Congress convenes, noting any changes in sponsorship or scope.
- Examine detailed patent litigation outcomes and patent office decisions related to key drugs like Keytruda to assess the legitimacy of patents being challenged.
- Investigate lobbying disclosures and potential interactions between pharmaceutical companies and lawmakers to better understand the influence on drug patent policy.
- Analyze comparative data on drug prices, market entry times for generics/biosimilars, and patent protection length across different countries for broader context.
- Monitor patient access and pricing trends for biologics affected by similar patent strategies, to quantify the real-world impact of extended patents.
Readers interested in the full scope and detailed findings of this issue should consult the original ICIJ investigation titled Cancer Calculus for comprehensive evidence and reporting.
Source & verification
Primary source: ICIJ · November 13, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EudraGMDP database
What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…

Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2025
Evidence Dossier: Antimicrobial Resistance Trends in the EU/EEA 2025 Antimicrobial Resistance Trends in the EU/EEA: Evidence from the 2025 EARS-Net Report What is established…

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update
Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment What is established Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella…